NCT03137160

An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Ohio State University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum

Detailed description

This is a Phase II study that will be open label and include a total of five patients who will receive the investigational product. These patients will have histological testing to rule out competing etiologies and require 3rd party adjudication/confirmation on agreement of the diagnosis. These patients will undergo 12 weeks of ixekizumab dosed every 2 weeks with follow-up until week 16.

Conditions

• Pyoderma Gangrenosum

Interventions

Type	Name	Description
BIOLOGICAL	Ixekizumab	Injection

Timeline

• Start date: 2017-05-04
• Primary completion: 2018-08-16
• Completion: 2018-08-16
• First posted: 2017-05-02
• Last updated: 2024-02-23
• Results posted: 2022-06-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study